{"document_type": "article", "snippet": "With questions raised about the blood-testing company\u2019s technology, its purported $9 billion valuation now looks overestimated.", "type_of_material": "News", "web_url": "http://www.nytimes.com/2015/10/28/business/dealbook/theranos-under-fire.html", "subsection_name": "DealBook", "blog": [], "section_name": "Business Day", "source": "The New York Times", "pub_date": "2015-10-28T00:00:00Z", "word_count": "973", "slideshow_credits": null, "news_desk": "Business", "byline": {"original": "By RICHARD BEALES", "person": [{"role": "reported", "lastname": "BEALES", "rank": 1, "organization": "", "firstname": "Richard"}]}, "abstract": null, "keywords": [{"value": "Theranos Inc", "rank": "1", "name": "organizations", "is_major": "N"}, {"value": "Holmes, Elizabeth (1984- )", "rank": "2", "name": "persons", "is_major": "N"}, {"value": "Tests (Medical)", "rank": "3", "name": "subject", "is_major": "N"}], "print_page": null, "multimedia": [], "lead_paragraph": "With questions raised about the blood-testing company\u2019s technology, its purported $9 billion valuation now looks overestimated.", "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Theranos Under Fire"}, "_id": "562fea1d38f0d8595b45cab5"}